New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib

Ixazomib is the first oral proteasome inhibitor to be approved, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was on the basis of results from the phase 3, double-blind, placebo-controlle...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Paul G, Kumar, Shaji, Laubach, Jacob P, Paba-Prada, Claudia, Gupta, Neeraj, Berg, Deborah, van de Velde, Helgi, Moreau, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573039/
https://www.ncbi.nlm.nih.gov/pubmed/28860887
http://dx.doi.org/10.2147/JBM.S102328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573039/
https://www.ncbi.nlm.nih.gov/pubmed/28860887
http://dx.doi.org/10.2147/JBM.S102328

Ejemplares similares